The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Open accessAbstract
Background: Microglia plays crucial roles in Alzheimer’s disease (AD) development. Triggering receptor expressed on myeloid cells 2 (TREM2) in association with DAP12 mediates signaling affecting microglia function. Here we study the negative regulation of TREM2 functions by leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2), an inhibitory receptor bearing ITIM motifs. Methods: To specifically interrogate LILRB2-ligand (oAβ and PS) interactions and microglia functions, we generated potent antagonistic LILRB2 antibodies with sub-nanomolar level activities. The biological effects of LILRB2 antagonist antibody (Ab29) were studied in human induced pluripotent stem cell (iPSC)–derived microglia (hMGLs) for migration, oAβ phagocytosis, and upregulation of inflammatory cytokines. Effects of the LILRB2 antagonist antibody on microglial responses to amyloid plaques were further studied in vivo using stereotaxic grafted microglia in 5XFAD mice. Results: We confirmed the expression of both LILRB2 and TREM2 in human brain microglia using immunofluorescence. Upon co-ligation of the LILRB2 and TREM2 by shared ligands oAβ or PS, TREM2 signaling was significantly inhibited. We identified a monoclonal antibody (Ab29) that blocks LILRB2/ligand interactions and prevents TREM2 signaling inhibition mediated by LILRB2. Further, Ab29 enhanced microglia phagocytosis, TREM2 signaling, migration, and cytokine responses to the oAβ-lipoprotein complex in hMGL and microglia cell line HMC3. In vivo studies showed significantly enhanced clustering of microglia around plaques with a prominent increase in microglial amyloid plaque phagocytosis when 5XFAD mice were treated with Ab29. Conclusions: This study revealed for the first time the molecular mechanisms of LILRB2-mediated inhibition of TREM2 signaling in microglia and demonstrated a novel approach of enhancing TREM2-mediated microglia functions by blocking LILRB2-ligand interactions. Translationally, a LILRB2 antagonist antibody completely rescued the inhibition of TREM2 signaling by LILRB2, suggesting a novel therapeutic strategy for improving microglial functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, Aβ can interact with the leukocyte immunoglobulin-like receptor B2 (LilrB2) and negatively mediate synapses and memory.585”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [585]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering key features in protein structures with the new ENDscript server
Robert, X., & Gouet, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku316 · Cited by 7,053
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Background Alzheimer’s disease (AD), the main cause of dementia, is a neurodegenerative disorder with limited treatment options [1, 2].”
BackgroundKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 1×
“This stage-dependent effect of LILRB2 in AD is consistent with the perplexing roles that TREM2 plays in AD [85, 86].”
ResultSelf-citationMicroglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999 · cited 1×
“Microglia, brain-resident myeloid cells, play pivotal roles in AD development by regulating brain homeostasis [8] and neuroinflammation [9], promoting Aβ plaque phagocytic clearance [10], and clustering and limiting diffusion of Aβ plaques [11] and tau tangles [12].”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578 · cited 1×
“Background Alzheimer’s disease (AD), the main cause of dementia, is a neurodegenerative disorder with limited treatment options [1, 2].”
BackgroundDisease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“Since disease-associated-microglia (DAM) gene studies currently reported mostly involve AD mouse models, 5XFAD and APPPS1, and mice have no LILRB2, we are not able to confirm whether LILRB2 is one of the DAM genes [60].”
BackgroundTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 2×
“In addition, TREM2 deficiency curtails anabolic and energetic metabolism demonstrated by ER stress, defective mTOR signaling, reduced ATP levels, and biosynthesis pathways [71].”
BackgroundChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 2×
“The immunoreceptor tyrosinebased switch motifs (ITSMs) in PD-1 play crucial roles in mediating the inhibition of CD3 as demonstrated by mutation studies [69].”
BackgroundDirect Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors
Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B., & Lanier, L. L. (2002) · Science · doi:10.1126/science.1070884 · Cited by 1,230 · cited 2×
“Association with DAP12 allows ligands to trigger NFAT signaling and induce GFP expression by binding to extracellular LILRB2 [43, 44] (Supplementary Fig.”
BackgroundSelf-citation
Research works printed but not linked: 2
- Ferreira ST, et al. Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci. 2015;9:191.
- Walker DG. Defining activation states of microglia in human brain tissue: an unresolved issue for Alzheimer’s disease. Neuroimmunol Neuroinflammation. 2020;7(3):194–214.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E. J., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00550-7 · Cited by 202
“Together with the decreased levels of BACE1 and amyloid-β 40 in this subtype compared to controls (Table 1), suggesting decreased amyloid metabolism, these genetic factors suggests that impaired clearance mechanisms contribute to AD pathogenesis in subtype 4.”
BackgroundZhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141
Self-citationMicroglia as hunters or gatherers of brain synapses
Pereira‐Iglesias, M., Maldonado-Teixidó, J., Melero, A., Piriz, J., Galea, E., Ransohoff, R. M., & Sierra, A. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01818-w · Cited by 87
“On the other hand, microglial process motility occurs in the minute range, as they move 1.0–1.5 μm min −1 in awake mice 42 .”
InfluentialTherapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM
Ma, C., Chen, J., Ji, J., Zheng, Y., Liu, Y., Wang, J., Chen, T., Chen, H., Chen, Z., Zhou, Q., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167449 · Cited by 50
Metadata
- Authors
- Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., Huang, T. Y., Zhao, Y., Zhang, C., Xu, H., Tong, Q., Zhang, N., & An, Z.
- Affiliations
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- The University of Texas Southwestern Medical Center (US)
- Research Institute for Microbial Diseases, The University of Osaka (JP)
- Memorial Hermann (US)
- Xiamen University (CN)
- Corresponding author
- Zhang, Ningyan
- An, Zhiqiang
- ORCID
- Venue
- Molecular Neurodegeneration
- Published
- 2022-06-18
- Volume
- 17
- Issue
- 1
- Pages
- 44-44
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC9206387
- OpenAlex
- W4283069055
- Cited by
- 54
- References
- 88
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 15 · 2023: 7 · 2022: 3
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Prevention and Research Institute of Texas (RP150551 and RP190561)
- Welch Foundation (AU-0042-20030616)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- LILRB2, TREM2, microglia, Alzheimer's disease, inhibitory receptors, ITIM, amyloid-beta, phosphatidylserine, microglial phagocytosis, microglial migration, inflammatory cytokines, amyloid plaques, 5xFAD mice, iPSC-derived microglia, DAP12
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Ligands, Membrane Glycoproteins, Receptors, Immunologic, Microglia, Mice, Induced Pluripotent Stem Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. https://app.cochat.ai/papers/10.1186/s13024-022-00550-y
- The paper
- Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., Huang, T. Y., Zhao, Y., Zhang, C., Xu, H., Tong, Q., Zhang, N., & An, Z. (2022). LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-022-00550-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.